The estimated Net Worth of Paul T Quinlan is at least $2.86 Million dollars as of 13 March 2024. Mr Quinlan owns over 41,824 units of Cymabay Therapeutics Inc stock worth over $2,282,110 and over the last 7 years he sold CBAY stock worth over $0. In addition, he makes $578,820 as Gen. Counsel und Chief Compliance Officer & Corp. Sec. at Cymabay Therapeutics Inc.
Sign up
Mr Quinlan CBAY stock SEC Form 4 insiders trading
Mr has made over 10 trades of the Cymabay Therapeutics Inc stock since 2023, according to the Form 4 filled with the SEC. Most recently he exercised 41,824 units of CBAY stock worth $329,991 on 13 March 2024.
The largest trade he's ever made was exercising 53,000 units of Cymabay Therapeutics Inc stock on 15 September 2023 worth over $155,820. On average, Mr trades about 7,490 units every 17 days since 2018. As of 13 March 2024 he still owns at least 70,262 units of Cymabay Therapeutics Inc stock.
You can see the complete history of Mr Quinlan stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Mr. Paul T. Quinlan biography
Paul T. Quinlan is the Gen. Counsel, Chief Compliance Officer & Corp. Sec. at Cymabay Therapeutics Inc.
What is the salary of Mr Quinlan?
As the Gen. Counsel und Chief Compliance Officer & Corp. Sec. of Cymabay Therapeutics Inc, the total compensation of Mr Quinlan at Cymabay Therapeutics Inc is $578,820. There are 6 executives at Cymabay Therapeutics Inc getting paid more, with Sujal Shah having the highest compensation of $2,556,470.
How old is Mr Quinlan?
Mr Quinlan is 58, he's been the Gen. Counsel und Chief Compliance Officer & Corp. Sec. of Cymabay Therapeutics Inc since . There are 6 older and 10 younger executives at Cymabay Therapeutics Inc. The oldest executive at Cymabay Therapeutics Inc is Robert Wills, 66, who is the Independent Chairman of the Board.
What's Mr Quinlan's mailing address?
Paul's mailing address filed with the SEC is C/O CYMABAY THERAPEUTICS, INC., 7601 DUMBARTON CIRCLE, FREMONT, CA, 94555.
Insiders trading at Cymabay Therapeutics Inc
Over the last 10 years, insiders at Cymabay Therapeutics Inc have traded over $17,635,452 worth of Cymabay Therapeutics Inc stock and bought 2,170,647 units worth $6,725,086 . The most active insiders traders include Capital Advisors Llc Aghaza..., Kurt Von Emster und Carl Goldfischer. On average, Cymabay Therapeutics Inc executives and independent directors trade stock every 37 days with the average trade being worth of $1,796,241. The most recent stock trade was executed by Sujal Shah on 13 March 2024, trading 139,119 units of CBAY stock currently worth $656,642.
What does Cymabay Therapeutics Inc do?
cymabay therapeutics is a clinical-stage biopharmaceutical company located in the san francisco bay area focused on developing therapies to treat metabolic diseases with high unmet medical need or serious rare and orphan diseases. we are committed to developing breakthrough medicines that improve the lives of patients and their families. cymabay was seeded with the assets from an earlier metabolic disease company in which more than $120m was invested to produce a robust pipeline.
What does Cymabay Therapeutics Inc's logo look like?
Complete history of Mr Quinlan stock trades at Cymabay Therapeutics Inc
Cymabay Therapeutics Inc executives and stock owners
Cymabay Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Sujal Shah,
President, Chief Executive Officer, Director -
Charles McWherter,
Senior Vice President, Chief Scientific Officer -
Klara Dickinson,
Chief Regulatory and Compliance Officer -
Daniel Menold,
Vice President - Finance -
Sujal A. Shah,
Pres, CEO & Director -
Dr. Charles A. McWherter Ph.D.,
Chief Scientific Officer -
Paul T. Quinlan,
Gen. Counsel, Chief Compliance Officer & Corp. Sec. -
Robert Wills,
Independent Chairman of the Board -
Kurt von Emster,
Independent Director -
Paul Truex,
Independent Director -
Caroline Loewy,
Independent Director -
Dr. Dennis D. Kim M.B.A., M.D., MBA,
Chief Medical Officer -
Becki Filice,
Sr. VP of Portfolio & Product Leadership -
Klara A. Dickinson-Eason,
Chief Regulatory & Quality Assurance Officer -
Dr. Robert L. Martin,
Sr. VP of Manufacturing & Nonclinical Devel. -
Patrick J. O'Mara,
Sr. VP of Bus. Devel. -
Ken Boehm,
Sr. VP of HR -
Daniel Menold,
VP of Fin. -
Evan A. Stein,
Director -
Robert F. Booth,
Director -
Carl Goldfischer,
Director -
Pol F Boudes,
Chief Medical Officer -
Robert J. Weiland,
Director -
Kirk Rosemark,
V.P. Regulatory & Quality -
Wart Harold Van,
President and CEO -
Emster Kurt Von,
Director -
Thomas G Wiggans,
-
Paul T Quinlan,
General Counsel -
Eric Lefebvre,
-
Harish Shantharam,
Chief Financial Officer -
Lewis J Stuart,
Chief Commercial Officer -
Patrick J. O Mara,
VP, Business Development -
Robert L. Martin,
Sr. Vice President -
Capital Advisors Llc Aghaza...,
-
Edward Penhoet,
Director -
Louis G Lange,
Director -
Hari Kumar,
Director -
Janet Dorling,
-
Dennis D Kim,
Chief Medical Officer